RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Recursion Pharmaceuticals (RXRX) Stock: Buy, Sell, or Hold?
$3.59
+0.04 (+1.13%)
â˛
5d:
-7.47%
30d:
-6.39%
90d:
+8.46%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect RXRX Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (58%)
Quality Score
50/100
Position
SLIGHTLY LOW
30-Day Fair Range
$3.56 â $4.24
Position: SLIGHTLY LOW
Forward P/E & Valuation
-4.4x
Next 12M consensus est.
Wall Street Target
$7.32
+103.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$3.42 / $4.52
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: RXRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 3, 2026 at $3.68 · last confirmed Nov 5, 2026
Strength: 6.8/10
Get Alerted When RXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: RXRX is currently trading at $3.59, which is considered slightly low relative to its 30-day fair value range of $3.56 to $4.24.
Technical Outlook: Technically, RXRX is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.51.
Market Sentiment: RXRX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.32 (+103.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RXRX is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.51.
Market Sentiment: RXRX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.32 (+103.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.56 -
$4.24
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Trading Range & Key Levels
30-Day Trading Range
$3.56 -
$4.24
Current vs Trading Range
SLIGHTLY LOW
Support Level
$3.42
Resistance Level
$4.52
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding RXRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 103.8% below Wall St target ($7.32)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.35
Wall Street Target
$7.32
(+103.8%)
Revenue Growth (YoY)
258.5%
Share RXRX Analysis
Share this live RXRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (RXRX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Recursion Pharmaceuticals ($RXRX) reported durable FAP data for REC-481 and early clinical activity for REC-1245, while partnerships and financing extended cash runway into 2029.
Key Retail Themes:
Drug development progress
Partnerships and financing
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 34 SELL |
Advanced RXRX Option Strategies
Professional options setups generated by AI based on today's RXRX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive RXRX Research Pages
